Stockreport

ImmunityBio, LadRx end licensing deal for cancer drug [Seeking Alpha]

XOMA Royalty Corporation  (XOMA) 
Last xoma royalty corporation earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.xoma.com/investor-relations
PDF agreement to terminate a licensing deal for aldoxorubicin, an investigational therapy targeted at soft tissue sarcoma and other cancers. XOMA Corporation ( NASDAQ: R [Read more]